Taysha Gene Therapies, Inc. 10-K Cybersecurity GRC - 2024-03-19

Page last updated on April 11, 2024

Taysha Gene Therapies, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-19 16:15:31 EDT.

Filings

10-K filed on 2024-03-19

Taysha Gene Therapies, Inc. filed an 10-K at 2024-03-19 16:15:31 EDT
Accession Number: 0000950170-24-033484

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity. Risk management and strategy We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data, or Information Systems and Data. Our information technology team, led by our Vice President of Engineering and Operations, helps identify, assess, and manage our cybersecurity threats and risks. Our information technology team assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example analyzing threat reports, conducting audits, and using intelligence feeds. Depending on the environment and systems, we implement and maintain various technical, physical, and organizational measures, processes, standards, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, employee training, access controls, cyber insurance, and systems monitoring. Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. For example, our senior management along with our information technology team evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk. We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example cybersecurity software providers, managed cybersecurity service providers, and dark web monitoring services. We use third-party service providers to perform a variety of functions throughout our business, such as contract research organizations, contract manufacturing organizations, and hosting companies. We have a vendor management process to manage cybersecurity risks associated with our use of these providers which includes risk assessments and audits. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider. For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including If our, or our vendors , information technology systems or data is or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to regulatory investigations or action litigation fines and penalties interruptions to our operations such as our clinical trials claims that we breached our data privacy and security laws harm to our reputation a loss of customers or sales and other adverse consequences. Governance Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors Audit Committee is responsible for overseeing our cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats. Our cybersecurity risk assessment and management processes are implemented by certain Company management, including our Compliance Officer and Vice President of Engineering and Operations, both of whom have previously served in management roles at other public biotechnology companies. Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. Company management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. 84 Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of our legal team depending on the circumstances. Our information technology team works with our incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company s incident response plan includes reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.


Company Information

NameTaysha Gene Therapies, Inc.
CIK0001806310
SIC DescriptionBiological Products, (No Diagnostic Substances)
TickerTSHA - Nasdaq
Website
Category
Emerging growth company
Fiscal Year EndDecember 30